Recurrence of Prostate Cancer Detected Earlier with Innovative PSMA-Ligand PET/CT

“A recent study reported in The Journal of Nuclear Medicine compared use of the novel Ga-68-PSMA-ligand PET/CT with other imaging methods and found that it had substantially higher detection rates of prostate-specific membrane antigen (PSMA) in patients with biochemical recurrence after radical prostatectomy. Discovering a recurrence early can strongly influence further clinical management, so it is especially noteworthy that this hybrid PSMA-ligand identified a large number of positive findings in the clinically important range of low PSA-values (<0.5ng/mL).

“According to the CDC, prostate cancer is the most common cancer among men in the United States, after non-melanoma skin cancer. While many men with prostate cancer die from other causes, prostate cancer remains one of the leading causes of cancer death among men of all races. Treatment and survival after recurrence depend on many factors, but early detection of the recurrence is certainly key.

“Matthias Eiber, MD, corresponding author of the study, noted, ‘The study is the first to examine this highly promising PET tracer in the use of a homogeneous patient collective consisting of only those with biochemical recurrence after radical prostatectomy. It found superb detection rates compared to other tracers, like choline, or imaging modalities, like MRI. For patients, this means that the referring urologist can receive earlier and more precise information about the site and extent of metastatic disease. Physicians will also be better able estimate whether a PSMA-PET scan might be useful in a specific setting.’ “


PSMA-Based Imaging Traces Even Treatment-Resistant Prostate Cancer

“Anti-androgen hormonal therapy, also called chemical castration, can be an important defense against further disease progression for patients with prostate cancer that has traveled and grown in other areas, or metastasized—but some cases simply do not respond to this treatment. A groundbreaking molecular imaging agent has been developed to help clinicians find as much cancer as possible, whether it is responding favorably or not, in an effort to improve clinical decision making for these patients, say researchers at the Society of Nuclear Medicine and Molecular Imaging’s 2014 Annual Meeting.”


Progenics Pharmaceuticals Announces the Completion of Enrollment of Chemotherapy Naive Cohort in Phase II Trial of PSMA ADC

“Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) an oncology company focused on the development of innovative approaches to targeting and treating prostate cancer, announced today the completion of enrollment in the chemotherapy naïve cohort in its Phase II trial of PSMA ADC.   This cohort of 36 chemotherapy naïve prostate cancer patients, all of whom progressed on hormonal therapies, was added to the Phase II trial following positive response to PSMA ADC in patients in the chemotherapy experienced setting.”

Editor’s note: This story is about clinical trial NCT01695044. The trial is testing a treatment called PSMA ADC for patients with metastatic, castration-resistant prostate cancer. Clinical trials can be good treatment options for some patients. Learn more about them here.


What's in a Label? Radioimmunotherapy for Metastatic Prostate Cancer

“Prostate cancer has a highly tumor-restricted prostate-specific membrane antigen (PSMA) and may be the ideal solid-organ malignancy for treatment with radioimmunotherapy. Encouraging results using lutetium-177-labeled anti-PSMA monoclonal antibody J591 from a Phase II study by Tawaga et al. support the continued clinical and preclinical development of radioimmunotherapy for solid tumors.”


New Clinical Trial Investigates Novel Lung Cancer 'Nanomedicine'

A new phase II clinical trial is investigating the new cancer drug BIND-014 as a second-line treatment for non-small cell lung cancer (NSCLC). BIND-014 is part of a group of ‘nanoengineered’ drugs called Accurins, which consist of: 1) targeting particles that direct them preferentially to the disease site–in the case of BIND-014, these particles bind to PSMA, a protein expressed on cancer cells; 2) a ‘stealth layer’ protecting them from the body’s immune system; 3) a controlled-release structure ensuring that the ‘payload’ is released at the optimal rate; and 4) the drug’s actual payload–in the case of BIND-014, the chemotherapy agent docetaxel (Taxotere). Accurins are designed to maximize the drug concentration delivered to the tumor, while minimizing toxicity to healthy tissues.


Novel Imaging Tools and Therapeutics Take Advantage of Prostate Cancer Biomarker


A new way to detect metastatic prostate tumors using molecular imaging has shown promise in an early phase clinical trial. The noninvasive technique takes advantage of a prostate cancer-specific marker on the surface of prostate cancer cells. Continue reading…


New Imaging Technique May Improve Detection of Metastatic Prostate Cancer Cells

A novel imaging technique is being studied as a tool to specifically detect prostate cancer cells located within the prostate gland, along with prostate cancer cells that have metastasized to other sites of the body. The technique uses a radiolabeled amino acid compound called Tc-99m MIP-1404, which is injected into the blood stream and then attaches to the PSMA enzyme located on prostate cancer cells. The radiolabeled prostate cancer cells are then detected with a computed tomography (CT) scan. In phase I patient trials, Tc-99m MIP-1404 was ready to be imaged by CT scan within 1 hour after injection into the body and pointed out more tumors than standard bone scans. Phase II clinical trials are ongoing.


Phase II Study of Lutetium-177 Labeled Anti-Prostate-Specific Membrane Antigen (PSMA) Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer

“Purpose: To assess the efficacy of a single infusion of radiolabeled anti-prostate specific membrane antigen monoclonal antibody J591 (177Lu-J591) by PSA decline, measurable disease response, and survival.”


Scientists Hope to Develop New Do-It-Yourself Prostate Cancer Test

Scientist at the University of California Irvine developed new technology that can detect a prostate cancer marker called prostate-specific membrane antigen (PSMA) in urine. The technology combines protein receptors with pencil-like viruses, creating a sensor that is inexpensive, resilient, and easy to mass produce. Human clinical trials have not started yet, but the scientists hope to market the test as an at-home prostate cancer test, similar to over-the-counter pregnancy tests.